LTP.ASX: SPONTAN Real-World Study Reports 93% Response

SPONTAN Real-World Study Reports 93% Response

Stock	LTR Pharma Ltd (LTP.ASX)
Release Time	11 Aug 2026, 8:32 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

LTR Pharma Reports Positive SPONTAN Real-World Study Results

Key Points

93% response rate among men seeking greater convenience and spontaneity
64% of post-prostatectomy patients reported improved erectile hardness and penetration
57% response among difficult-to-treat subgroup with prior oral ED therapy failures

Full Summary

LTR Pharma Limited announced the outcomes of a real-world study of 147 men using SPONTAN®, its rapid-onset intranasal vardenafil spray. The study found a 93% response rate among men seeking greater convenience and spontaneity, 64% among post-prostatectomy patients, and 57% among those with prior oral ED therapy failures. The findings suggest SPONTAN may offer an alternative treatment option for men who do not respond well to conventional oral ED therapies. The study results will be presented at the Australian Prostate Cancer Conference and submitted for peer review.

Outlook

LTR Pharma plans to present the study data at APCC, evaluate a prospective study in the post-prostatectomy population, and implement activities ahead of ROXUS U.S. commercial availability.